Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + zanubrutinib
- Development stage
- Unknown
- Lead developer
- Jiangsu Provincial People's Hospital
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Pola-ZRCHP is an investigational chemoimmunotherapy combination regimen being evaluated for the treatment of previously untreated diffuse large B-cell lymphoma (DLBCL), specifically targeting high-risk molecular subtypes such as MCD, BN2, and N1. The regimen builds upon the Pola-R-CHP backbone (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone) by adding zanubrutinib, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor. Polatuzumab vedotin is an antibody-drug conjugate (ADC) targeting CD79b, delivering the microtubule inhibitor monomethyl auristatin E (MMAE). Rituximab is an anti-CD20 monoclonal antibody. Cyclophosphamide and doxorubicin are standard cytotoxic chemotherapy agents. The addition of zanubrutinib aims to enhance efficacy by inhibiting B-cell receptor signaling, which is often constitutively active in specific DLBCL subtypes.
- Other names
- Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone
02
Targets
CD20 (B-lymphocyte antigen CD20)BTK (Bruton tyrosine kinase)B-cell antigen receptor complex-associated protein beta chainTOP2A (DNA topoisomerase II)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + zanubrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + zanubrutinib.